Neurogene Inc. (NASDAQ: NGNE) President and Chief Financial Officer Christine Mikail Cvijic executed the sale of 2,558 shares of the companys common stock on March 26, 2026, receiving approximately $55,315 for the shares, according to a Form 4 filing with the Securities and Exchange Commission.
The reported transaction shows execution prices spanning $21.10 to $21.91 per share. Company stock has since moved lower, trading at $19.30 at the most recent market check, and exhibiting the same choppy trading behavior that has characterized NGNE this year - shares are down about 6% year-to-date.
According to the regulatory filing, the disposition was carried out to meet tax withholding obligations arising from the vesting of a restricted stock unit (RSU), and the sale was mandatory upon vesting. Cvijic did not elect for the sale; it was performed as a required withholding transaction tied directly to the RSU vesting event.
After the March 26 sale, Cvijic directly holds 103,240 shares of Neurogene common stock. That total includes multiple unvested RSU grants with specified vesting schedules:
- 10,635 restricted stock units granted on March 13, 2024, scheduled to vest on March 13, 2027;
- 13,533 restricted stock units granted on March 26, 2025, set to vest in equal annual installments on March 26, 2027 and March 26, 2028;
- 22,000 restricted stock units granted on February 20, 2026, that will vest in equal annual installments on February 20, 2027, February 20, 2028, and February 20, 2029.
Of Cvijics remaining shares, 19,200 are held jointly with her spouse, David Cvijic, the filing shows.
Investor analysis cited in public commentary notes that NGNE appears undervalued at prevailing market levels and that the company maintains a balance sheet with more cash than debt. That assessment is reflected in research material available through the analysis platform referenced in the filing.
Beyond insider activity, Neurogene has recently achieved a notable regulatory milestone. The U.S. Food and Drug Administration granted Breakthrough Therapy designation to NGN-401, the company's investigational gene therapy for Rett syndrome. The designation was based on interim efficacy and safety data from a Phase 1/2 trial that the company reports showed clinically meaningful improvements across multiple Rett syndrome domains.
Neurogene also reported that it completed enrollment for its Embolden Phase 1/2 study of NGN-401, with more than half of the patients already dosed and dosing expected to finish by the second quarter of 2026.
Market analysts have responded to those developments with reiterated coverage. H.C. Wainwright maintained a Buy rating and a $70 price target, noting progress on the registrational study and manufacturing pathway. William Blair reiterated an Outperform rating, citing continued program progress despite external challenges such as a bad flu season. Leerink Partners also reiterated an Outperform view and held a $70 price target, calling attention to advancement in the Rett syndrome program.
Taken together, the regulatory progress and clinical trial milestones are the primary drivers of analyst commentary, while the recent, mandatory insider sale reflects a routine tax-withholding mechanism tied to equity compensation rather than an elective cashing out by the executive.
Investors tracking NGNEs insider activity, clinical-readout timetable, and the company's liquidity profile will likely continue to monitor both ownership dynamics and operational progress closely as the company advances its clinical program and manufacturing plans.